Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

TDT is a type of beta-thalassemia characterized by severe anemia and requires a lifelong dependence on red blood cell transfusions and patients are frequently hospitalized. SCD is a progressively ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

Transfusion-dependent β-thalassemia (TDT ... and health care utilization of patients with TDT, a rare genetic blood disorder characterized by the body's inability to produce sufficient hemoglobin.

even in iOS 18.2. Apple has also released the first macOS Sequoia 15.2 developer beta with new Apple Intelligence tools as well, 9to5Mac reports. Genmoji apparently isn’t included in that beta.

NEW YORK – Editas Medicine on Tuesday said it will seek a global development and commercialization partner or an out-licensing deal for an investigational treatment for severe sickle cell disease and ...

Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a ...

On August 7, 2024, VRTX announced a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access CASGEVY. This CRISPR/Cas9 gene-edited therapy ...